Delving into the Latest Updates on Mesenchymal Stem Cells(Cell2Cure ApS) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Stem cell replacements

Therapeutic Areas

Nervous System Diseases

Active Indication

Autistic Disorder

Inactive Indication

Diabetic foot ulcer

Originator Organization

Cell2Cure ApS

Active Organization

Cell2Cure ApS

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The ASC - Autism Pilot Study is a single center randomized open dose titrating phase I clinical intervention pilot trial with the aim of investigating safety and treatment effect of an allogeneic adipose tissue derived mesenchymal stromal cell product (C2C_ASC) in children with autism spectrum disorder (ASD) and gastrointestinal symptoms.

Start Date09 Jun 2023

Sponsor / Collaborator

Cell2Cure ApS

NCT05595681

/ TerminatedPhase 1

Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients. A Phase I Pilot Study.

The STEMFOOT Pilot Study is a single center randomized open phase I clinical intervention pilot trial with the aim of investigating the treatment effect of an allogenic adipose-derived mesenchymal stromal cell product (C2C_ASC) compared to conventional optimal treatment on healing and complications of foot ulcers in diabetes patients.

Start Date15 Dec 2022

Sponsor / Collaborator-

100 Clinical Results associated with Mesenchymal Stem Cells(Cell2Cure ApS)

Login to view more data

100 Translational Medicine associated with Mesenchymal Stem Cells(Cell2Cure ApS)

Login to view more data

100 Patents (Medical) associated with Mesenchymal Stem Cells(Cell2Cure ApS)

Login to view more data

100 Deals associated with Mesenchymal Stem Cells(Cell2Cure ApS)

Login to view more data